Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Genpact Has Been Working With embecta's To Support Its Spin-Off Into An Independent Diabetes Care Company

Author: Benzinga Newsdesk | July 29, 2024 08:17am

Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector

NEW YORK, July 29, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta (NASDAQ:EMBC), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.

Posted In: EMBC G


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist